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Abstract
Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a
multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is
well tolerated, concern for its safety has been expressed. Celecoxib (CelebrexH) is a selective cyclooxygenase-2 (COX-2)
inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between
celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone
reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth and increased
apoptosis. To better understand the molecular mechanisms underlying the synergistic antitumor activity of the
combination, we investigated the expression profile of the combination-treated liver cancer cell lines using microarray
analysis. Combination treatment significantly altered expression levels of 1,986 and 2,483 transcripts in HepG2 and Huh7
cells, respectively. Genes functionally involved in cell death, signal transduction and regulation of transcription were
predominantly up-regulated, while genes implicated in metabolism, cell-cycle control and DNA replication and repair were
mainly down-regulated upon treatment. However, combination-treated HCC cell lines displayed specificity in the expression
and activity of crucial factors involved in hepatocarcinogenesis. The altered expression of some of these genes was
confirmed by semi-quantitative and quantitative RT-PCR and by Western blotting. Many novel genes emerged from our
transcriptomic analyses, and further functional analyses may determine whether these genes can serve as potential
molecular targets for more effective anti-HCC strategies.
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Introduction
Hepatocellular carcinoma (HCC) represents the fifth most
frequent cancer and the third most common cause of death from
cancer [1,2]. Although the clinical diagnosis and management of
early-stage HCC has improved significantly, HCC prognosis is still
extremely poor. Furthermore, advanced HCC is a highly
aggressive tumor with a low or no response to common therapies.
Therefore, new effective and well-tolerated therapy strategies are
urgently needed.
Sorafenib, a multikinase inhibitor which targets Raf kinases as
well as VEGFR-2/-3, PDGFR-b, Flt-3 and c-Kit, recently
received FDA and EMEA approval for the treatment of patients
with advanced HCC. However, the low tumor response rates and
the side effects associated with this monotherapy indicate the need
to investigate other new therapeutic options for HCC.
Targeted therapies have entered the field of anti-neoplastic
treatment and are used either alone or in combination with
conventional chemotherapy drugs. Molecular-targeted therapy
holds promise for HCC [3]. However, as in the majority of
cancers, the use of a single molecular targeted agent would
unlikely achieve a long-lasting remission or cure in HCC,
especially for late-stage disease. Combination therapy will be
therefore required, and it seems reasonable to speculate that a
combination of two or more agents will ultimately increase the
therapeutic gain.
HCC is usually the outcome of continuous injury and chronic
inflammation. An important mediator of inflammation is the
inducible gene cyclooxygenase-2 (COX-2). It is now well-
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established that COX-2 is an important molecular target for anti-
cancer therapies. COX-2 is chronically over-expressed in many
cancers, including HCC [4–8]. In HCC, we and other investiga-
tors have demonstrated that COX-2 inhibitors may have potential
therapeutic effects [9–13].
The rationale for combining sorafenib with COX-2 inhibitors in
HCC comes from data published by other authors [14] but also
from our own published data [12]. We demonstrated that
treatment of human HCC cells with a COX-2 inhibitor is
associated with the activation of ERK1/2, and that the inhibition
of the MEK/ERK signaling pathway by a MEK inhibitor
potentiates the antitumor activity of the inhibitor. Overall, our
results suggest that the MEK/ERK pathway does not mediate
cytotoxicity induced by COX-2 inhibitors but may protect cells
from death, which indirectly supports the role of the MEK/ERK
pathway in the survival signaling of HCC cells [12].
Therefore, based on these findings we tested the effects of a
combination of the selective COX-2 inhibitor celecoxib with
sorafenib. Synergistic anti-proliferative and pro-apoptotic effects
were obtained when using the combination of sorafenib with
celecoxib. In order to better understand the detailed mechanisms
of the cytotoxic effects of celecoxib and sorafenib, we also
investigated and compared the global gene expression of HCC
cells treated with either celecoxib or sorafenib, or the two drugs
applied in combination.
Materials and Methods
Reagents, Cell Culture, Cell Viability, Clonogenic and
Proliferation Assays
Celecoxib (CLX) was a gift of Pfizer Corporation Inc. (New
York, USA), sorafenib (SOR) was purchased from Alexis
Biochemical (Lausen, CH), and both drugs were dissolved in
dimethyl sulfoxide (DMSO). The human hepatocellular carcino-
ma cell lines HepG2 (a human hepatocarcinoma cell line; ATCC
HB-8065) and Huh7 [15] (a gift from Prof. Massimo Levrero,
Sapienza University of Rome, Rome, Italy) used in this study were
of a low narrow passage number and were maintained as
previously described [16]. All cells were kept at 5% CO2 and
37uC and routinely screened against mycoplasma contamination.
Cell viability assays were performed as previously reported [17].
The coefficient of drug interaction (CDI) was used to analyze
effects of drug combinations [18]. CDI is calculated as follows:
CDI=AB/(A6B). According to the absorbance of each group, AB
is the ratio of the combination groups to control group; A or B is
the ratio of the single agent group to control group. Thus, CDI
values less than, equal to or greater than 1 indicate that the drugs
are synergistic, additive or antagonistic, respectively. CDI less than
0.7 indicates that the drugs are significantly synergistic. In
addition, statistical analysis was performed using Student’s T test
(two-tailed). The criteria for statistical significance was p,0.05.
The effect of different inhibitor concentrations on cell viability
was also assessed using a clonogenic assay. For this analysis, 1.0–
1.56103 cells were plated in six-well plates in growth medium, and
after overnight attachment cells were exposed either to CLX and
SOR alone or their combinations or vehicle for 48 hours. The cells
were then washed with drugs-free medium and allowed to grow for
14 days in drugs-free conditions. Colonies containing more than
50 cells were counted. Relative colony formation was determined
by the ratio of the average number of colonies in treated cells to
the average number of colonies in cells treated with solvent
(DMSO). All experiments were performed in duplicate and
repeated twice.
Cell proliferation was determined by estimating the amount of
bromodeoxyuridine (BrdU) incorporation into DNA by a color-
imetric immunoassay (Roche Diagnostics GmbH, Mannheim,
Germany). In brief, 56103 cells were cultured in 96-well plates in
the different concentrations of CLX and SOR alone or their
combinations or vehicle for 24 hours. BrdU was then added at
10 mM final concentration. The cells were further incubated for an
additional 24 hours and subsequently fixed and treated with anti-
BrdU peroxidase according to the manufacturer’s instructions.
Color was developed by the addition of tetramethylbenzidine
substrate and measured at 490 nm. Color intensity and absor-
bance values directly correlated to the amount of BrdU
incorporated into DNA. Results were expressed as percentage
inhibition of BrdU incorporation over the control. Values were
expressed as means 6 SD of three separate experiments, each
performed in triplicate.
TUNEL Assays
The cells were cultured in 8-well chamber slides overnight. After
treatment for 24 hours with various concentrations of CLX and
SOR either alone or in combination, cells were washed twice with
PBS and fixed in 4% paraformaldehyde solution for 25 minutes at
room temperature. Apoptotic cells were detected by terminal
deoxynucleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL) assay using the DeadEndTM Colorimetric TUNEL
System Kit from Promega (Madison, WI), following the manu-
facturer’s instructions. The number of apoptotic cells was
determined by counting the percentage of brown-color positive
cells. At least 500 cells from two different cell preparations were
counted for each condition. Cells were visualized with an Axioskop
microscope (Zeiss, Germany).
Western Blotting Analyses
For Western blot analysis, whole cell lysates were obtained using
RIPA buffer (Cell Signaling Technologies Inc., Danvers, MA) and
Western blotting was performed as previously described [19], with
primary antibodies raised against survivin and TRIB3/TRB3
(Abcam Limited, Cambridge, UK), DDIT3/CHOP (Cell Signal-
ing Technologies Inc., Danvers, MA), b-actin, YAP1 and DKK1
(Sigma-Aldrich Srl, Milan, Italy).
Gene Expression Profiling and Data Analyses
Gene expression analysis was carried out using Agilent 44 K
Human Whole Genome Oligonucleotide Microarrays (containing
,44,000 genes), as previously described [20–23]. All microarray
experiments were performed in duplicate, using dye-swap during
labeling. The GeneSpring software (Agilent, Palo Alto, CA) was
used to generate lists of selected genes for different statistical and
visualization methods. Network and pathway analyses of the
microarray data were completed using the Ingenuity Pathway
Analysis (IPA) software (http://www.Ingenuity.com). The micro-
array data has been deposited to GEO database with accession
number GSE45340.
Semi-quantitative RT-PCR (sqRT-PCR) Analyses
Microarray data were validated for selected differentially
expressed genes by sqRT-PCR as previously described [21,23].
The b-actin gene was used as a reference gene. The following
sense and antisense primers were used, respectively, to amplify
human BIRC5 (59-GCATGGGTGCCCCGACGTTG-39 and 59-
GCTCCGGCCAGAGGCCTCAA-39), DDIT3 (CHOP) (59-
ATGGCAGCTGAGTCATTGCC-39 and 59-TCATGCTTGG-
TGCAGATTC-39), FABP1 (59-CTCTATTGCCACCATGAG-
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39), MT2A (59-AAGAAAAGCTGCTGCTCCTG-39 and 59-
TGGAAGTCGCGTTCTTTACAT-39), YAP1 (59-GGCAAA-
GACATCTTCTGGTCA-39 and 59-CATCATATTCTGCTG-
CACTGG-39) and b-actin (59-CACCACACCTTCTACAATGA-
GC-39 and 59-AGTACAGCTACGAGCAGTTCTTGTT-39).
PCR reactions were performed using the following parameters:
95uC for 5 min, 94uC for 30 sec, 62uC for HRK, LARP6, 60uC
for BIRC5, b-actin, FABP1, MT2A, YAP1, 58uC for DDIT3, and
72uC for 1 min followed by a final extension step of 72uC for
8 min. The number of cycles was adjusted to allow detection in the
linear range. Finally, PCR products were analyzed by electropho-
resis on agarose gel, photographed and quantified by densitomet-
ric scanning.
Quantitative RT-PCR (qRT-PCR) Analyses
Expression of selected genes was quantified by quantitative Real
Time PCR (qPCR) using Sybr Green fluorescence (Qiagen, Milan,
Italy) on StepOnePlus (Applied Biosystem). QuantiTect Primer
Assays for CCND1 (QT00495285), DDIT3 (CHOP)
(QT00082278), DKK1 (QT00009093), FGF19 (QT02452289),
FNDC3B (QT01882748), KLB (QT02454977), TRIB3
(QT00088543), LARP6 (QT00221445) were purchased from
QIAGEN (Milan, Italy) and amplified as recommended. Relative
expression was calculated using the comparative Ct method.
Expression of the gene of interest was calculated as fold induction
compared with control (DMSO) and was corrected with the
quantified expression level of b-actin (QT00095431).
Results
Combination of Celecoxib with Sorafenib Synergistically
Reduces Cell Viability, Cell Proliferation and Colony
Formation and Induces Apoptosis in HCC Cells
Using the MTS assay we first assessed the effects of sorafenib
(SOR) and celecoxib (CLX) on the viability of two human HCC
cell lines, HepG2 and Huh7, which display different characteristics
including differentiation, biological behavior and genetic defects,
COX-2 expression levels [21], as well as Raf/MEK/ERK
pathway activities [23]. As shown in Figure 1, treatment with
CLX and SOR for 48 hours effectively reduced viability in both
cell lines. After 72 hours of drug’s exposure, the IC50s of CLX
were 7669.9 and 72.560.7 mM in HepG2 and Huh7 cells,
respectively; the IC50s of SOR were 10.361.1 and 10.161.8 mM
in the same cells. Since COX-2 mRNA expression is undetectable
in HepG2 cells [10,21], the growth-inhibitory activity of CLX
would appear to be largely COX-2 independent in these cells [21].
In addition, the SOR-mediated growth-inhibitory activity would
appear to be independent of MEK/ERK pathway inactivation in
HepG2 cells, since as previously reported, the expression of
phospho-MEK and phospho-ERK1/2 is barely detectable in this
HCC cell line [23].
We next investigated the cytotoxic effects of the SOR+CLX
combination in both HCC cell lines using MTS assays (Figure 1).
The SOR+CLX combination displayed significantly increased
cytotoxicity compared to the single agents. CDI was used to
determine the type of interaction between the agents (Table 1). In
both cell lines strong synergy occurred when CLX was applied in
combination with SOR (Table 1).
The cytotoxic effects of combination treatment were further
confirmed using a clonogenic assay (Figure 2). Cells were treated
for 2 days with or without compounds, the medium was aspirated
and they were then washed with inhibitor-free medium. Cells were
allowed to grow for an additional 14 days. There was a dose-
dependent decrease in colony-forming ability due to combined
SOR+CLX treatments in both cell lines. Indeed, the SOR+CLX
combination at a fixed dose ratio resulted in a significant increase
in tumor cell killing as measured by colony formation assays
compared to the single agents (Figure 2).
Figure 1. Effect of celecoxib (CLX) and sorafenib (SOR)
individually and in combination on viability of HCC cells. Cell
vitality was assessed by the MTS assay. HepG2 and Huh7 cells were
treated for 48 h with the indicated concentrations of CLX and SOR
either alone or in combination. Data are expressed as the percentage of
control cells and are the means 6 SD of three separate experiments,
each of which was performed in triplicate. *p,0.05; **p,0.01 versus
sorafenib alone, #p,0.05; ##p,0.01 versus celecoxib alone.
doi:10.1371/journal.pone.0065569.g001
Table 1. CDI of the combination of sorafenib and celecoxib in
HepG2 and Huh7 cells.
HepG2 Huh7
Sorafenib (mM) Sorafenib (mM)
5 7.5 10 5 7.5 10
Celecoxib (mM) 25 0.890 0.640 0.510 0.898 0.833 0.760
50 0.708 0.502 0.639 0.732 0.661 0.639
75 0.544 0.470 0.552 0.691 0.612 0.624
doi:10.1371/journal.pone.0065569.t001
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Since the anti-growth effects of the individual or combined
treatments could be due to increased cell death and/or decreased
cell proliferation, we examined separately the drug’s effects on
apoptosis induction and DNA synthesis. With regard to apoptosis,
treatment of HepG2 and Huh7 cells with up to 50 mM CLX had
negligible effects on apoptosis induction as evaluated by TUNEL
assay (Figure 3A). Treatment with 7.5 or 10 mM SOR increased
the amount of apoptotic HepG2 cells to 3.460.85% and
5.561.4%, respectively. However, the SOR+CLX combination
significantly increased apoptosis in HepG2 cells compared to
treatment with either agent used alone (p,0.05), whereas in Huh7
cells no effect was observed (Figure 3B). The BrdU assay was used
to study the effects of the combination treatment on cell
proliferation. As shown on Figure 3C, the SOR+CLX combina-
tion had a strong synergistic effect on cell proliferation in both cell
lines, displaying CDI values less than 0.5 and 0.6 in all SOR+CLX
drugs combinations in HepG2 cells and Huh7 cells, respectively.
Transcriptomic Analysis Identifies Gene Expression
changes Common to Both and Unique to HepG2 and
Huh7 Cells Following Combination Treatment
To identify new potential mechanisms of the combined action of
celecoxib and sorafenib, their effects on global gene expression in
both cell lines were investigated and compared using DNA
microarray technology. Agilent 44 K Human Whole Genome
Oligonucleotide Microarrays (containing ,44,000 genes) were
used to identify global gene expression changes in the HCC cell
lines, following simultaneous treatment with 50 mM CLX and
7.5 mM SOR for 48 hours. These concentrations were empirically
estimated as the maximal drug concentrations which do not cause
a considerable reduction in cell viability (less than 20–30%) and/
or changes in cell morphology during the treatment period (data
not shown). All microarray experiments were performed in
duplicate applying dye-swaps to avoid labeling bias. Using this
approach, a total of 1,986 differentially-expressed genes with
expression levels $2 fold were identified in HepG2 cells, and
2,483 genes displayed $2 fold expression in Huh7 cells. Among
these, 975 genes or 1,382 genes were up-regulated and 1,011 or
1,111 genes were down-regulated in HepG2 and Huh7 cells,
respectively. It should be emphasized that in both HCC cell lines
Figure 2. Effect of celecoxib (CLX) and sorafenib (SOR) individually and in combination on growth of HCC cells. Cell growth of HepG2
and Huh7 cells was determined by clonogenic assay after treatment with CLX and SOR either alone or in combination. Cells were plated overnight
and exposed to CLX and SOR alone or in combination at the indicated concentrations for 48 h. After treatment each well was washed and the
experiment continued for 14 days in the absence of drugs. Surviving colonies were stained (left panel) and counted (right panel). Data are expressed
as a percentage of colony in control cells and are the means 6 SD of two separate experiments, each of which was performed in duplicate. *p,0.05;
**p,0.01 versus each agent alone.
doi:10.1371/journal.pone.0065569.g002
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Figure 3. Effect of celecoxib (CLX) and sorafenib (SOR) individually and in combination on apoptosis and cell proliferation. (A)
Detection of apoptosis by TUNEL assay. Photomicrographs of HepG2 cells treated for 24 h with the indicated concentrations of CLX and SOR either
alone or in combination. Apoptotic cells were visualized by TUNEL staining as described in the Materials and Methods section. (B) Quantitative
Sorafenib and Celecoxib in HCC
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the combined SOR+CLX treatment produced a predominant
reduction in genes associated with metabolism, cell-cycle control
and DNA replication and repair, as numerous genes involved in
DNA replication and repair were especially down-regulated in
HepG2 cells (see Table 2A and 2C). Genes functionally related to
cell death, signal transduction and regulation of transcription were
mostly up-regulated in both HepG2 and Huh7 cells (Table 2B and
2D). Genes implicated in cell growth and proliferation and
transport were proportionally up- and down-modulated in HepG2
cells, while they were mainly induced in Huh7 cells (Table 2).
Tables S1 and S2 display complete lists of the differentially-
expressed genes ($2-fold) in the SOR+CLX-treated HepG2 and
Huh7 cells, respectively.
Our transcriptomic analyses strongly confirmed the observed
synergistic effects of the combined treatment in HCC cells. We
previously investigated the molecular mechanisms (including gene
expression profiling) of celecoxib [21] and sorafenib [23]
cytotoxicity in HepG2 and Huh7 cells. Venn diagram analysis
based on the previously-published and the above gene lists were
indicative of a substantial number of differentially-expressed genes
that were exclusively modulated in both HCC cell lines only upon
the combined SOR+CLX treatment (Figure 4A). Moreover, the
majority of these uniquely modulated genes displayed evident
HepG2 or Huh7 cell specificity upon SOR+CLX treatment (see
Figure 4B). These data are in agreement with our previous
findings about the different molecular mechanisms of cytotoxic
action of celecoxib or sorafenib in HepG2 and Huh7 cells [21,23].
The above analyses also prompted us to evaluate whether
SOR+CLX-treated HepG2 and Huh7 cells could be distinguished
on the basis of their gene expression profiles. Following filtering on
2-fold signal intensity, we used a one-way ANOVA parametric test
(Welch t-test; variances not assumed equal) to select discriminatory
genes. Indeed, t test with a p-value cutoff of 0.005 selected 174
genes for which expression differed in HepG2 and Huh7 cells.
Clustering analysis based on the 174 genes list was performed
using the standard Condition Tree algorithm provided in Gene-
Spring, revealing the formation of two major cluster groups that
clearly distinguish HepG2 and Huh7 cells upon treatment
(Figure 4C). Ninety-nine genes from the 174-genes list were up-
regulated in HepG2-treated cells, compared to Huh7 cells. Major
classifications of these genes included cell proliferation, signal
transduction, metabolism and transport. Genes up-regulated in
Huh7-treated cells in comparison to HepG2 cells (75 genes) are
mainly involved in metabolism, signal transduction, regulation of
transcription, immune response and DNA replication and repair.
The 174 genes list is presented in Table S3.
Pathway and network analyses generated through the use of
Ingenuity Pathways Analysis (IPA) software confirmed the
common and distinct major functionally-related gene groups,
which were found to be differentially expressed in SOR+CLX-
treated HepG2 and Huh7 cells (Figure 5). Notably, the top
functional pathways down-regulated in both cell lines were those
related to cell- cycle, DNA replication, recombination and repair,
lipid metabolism and small molecule biochemistry (Figure 5B and
5D), while pathways associated with cell development and gene
expression were found to be commonly induced (Figure 5A and
5B). Pathways related to cell death and cell growth and
proliferation were both induced and suppressed in the two cell
lines, although, as expected, in each HCC cell line cell death
pathways were more strongly induced than suppressed (Figure 5A–
5D). The two HCC cell lines also displayed some differences upon
SOR+CLX treatment; thus, pathways associated with cell
assembly and organization were predominantly down-regulated
in HepG2 cells (Figure 5B), while pathways functionally related to
vitamin, mineral and amino acid metabolism were mostly down-
regulated in Huh7 cells (Figure 5D). Accordingly, pathways
associated with cellular movement, cell morphology, cell function
and maintenance and cell cycle were more strongly up-regulated
in HepG2 cells (Figure 5A), whereas Huh7 cells displayed specific
up-regulation of pathways related to carbohydrate metabolism,
molecular transport, small molecule biochemistry and DNA
replication, recombination and repair (Figure 5C).
A network analysis identified numerous highly significant
networks with a score $3 that were down- or up-regulated in
HepG2 and Huh7 cells upon combined SOR+CLX treatment. As
expected, for both HCC cell lines the five top-scoring up-regulated
networks were mainly associated with functions linked to cell death
and gene expression, while the top-scoring down-regulated
networks were mostly linked to cell cycle and metabolism (Table
S4). Here again, each of the two HCC cell lines displayed some
specificity in network modulation: thus for HepG2 cells, the five
top-scoring up-regulated networks were mostly associated with
protein biosynthesis and molecular transport (Table S4A), while
for Huh7 cells, the top-scoring up-regulated networks were
additionally linked to cell assembly and organization, cell function
and maintenance and cell cycle (Table S4B). Functional networks
coupled to DNA replication, recombination and repair were
specifically suppressed in HepG2 cells (Table S4C), while Huh7
cells displayed down-regulation of networks related to cellular
function and maintenance, RNA post-transcriptional modifica-
tion, cellular assembly and organization, molecular transport and
immune response (Table S4D).
Common networks, generated by merging the four top-scoring
networks that included both down- and up-regulated genes
(#2 fold), recognized some functionally-related gene nodes that
were specifically modulated in the two HCC cell lines upon
SOR+CLX treatment (Figure 6 and 7). In particular, in HepG2
cells a number of gene nodes implicated in cell cycle control and
DNA replication, recombination and repair (including ERBB2,
EPO, CCNE1, CDC25A, CCNB1, BIRC5, NDC80, BUB1,
PXN, KPNB1, KITLG, CDCA5, CDCA8, TCF3, CDH1,
CDKN3) were down-regulated, while gene nodes linked to cell
death (including ASNS, SOX4, EPAS1, S100P, IRS2, LCN2,
IGFBP1, TRIB3, PHLDA2, AURKB) were mostly induced, with
the exception of the AURKB gene node (Figure 6). Gene nodes
specifically down-regulated in Huh7 cells included a number of
cell cycle and transcription regulators (CCND1, CCNE1, TCF3,
FANCA, CENPF, FGFR3, ID1, ID2, ID3, MSX1 and members
of the NF-kB complex), as well as genes involved in RNA post-
transcriptional modification (CDKN2A, SREK, SRSF1), whereas
up-regulated nodes (including SP1, ATF3, SRSF1, BMP4, MSX1,
KLF4, JMJD6) were mostly associated with control of cell death
(Figure 7).
analysis of TUNEL-positive HepG2 and Huh7 cells. Data are expressed as the means 6 SD of two separate experiments. *p,0.05, versus each agent
alone. (C) Cell proliferation was assessed by BrdU assay. Cells were treated for 48 h with the indicated concentrations of CLX and SOR either alone or
in combination. Data are expressed as the percentage of the control cells and are the means 6 SD of three separate experiments. *p,0.05; **p,0.01
versus each agent alone.
doi:10.1371/journal.pone.0065569.g003
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Table 2. Selected differentially expressed ($2-fold) functional gene groups in HepG2 and Huh7 cells upon combined
sorafenib+celecoxib treatment.
A. Genes downregulated in HepG2 cells
metabolism ABAT, ABCD3, ABHD12, ACAA1, ACAT2, ACOT2, ACOX2, ACSF2, ACSL6, ACSS1, ACSS3, ADH4, ADH6, AFMID, AGMAT, AGPAT3, AGXT, AK4,
AKR1D1, AKR7A3, ALDH18A1, ALDH1A1, ALDH1B1, ALDH3A1, ALDH3A2, ALDH5A1, ALDH7A1, ALDOC, AMDHD1, AMT, AP1M2, APOA1, APOA4,
APOA5, APOB, APOC2, APOC3, APOF, APOM, ARSE, ASRGL1, ATAD2, ATP5B, ATP5J2, ATPIF1, B3GNT1, BCKDHB, BDH2, BHMT, C5orf4, CA14, CA5A,
CAT, CDO1, CEBPA, CHST13, CHST9, CNP, COQ3, CPOX, CRIP2, CRYL1, CST3, CTBP2, CYP3A5, DAK, DCXR, DDC, DGAT1, DGAT2, DHCR24, DHCR7,,
HFR, DHFRL1, DHRS1, DHRS2, DPYSL2, DTYMK, EBP, EBPL, ELOVL2, ENPP3, EPHX2, FABP1, FABP5, FADS1, FADS2, FBXO36, FDFT1, FDPS, FDXR,
FGA, FGB, FTCD, GALK1, GAMT, GCHFR, GDPD5, GGH, GLDC, GLT8D1, GLUD1, GLUD2, GM2A, GMNN, GPAM, GSTA1, GSTA2, GSTA4, GSTA5,
GSTM3, GSTM4, GYG2, HADH, HAMP, HGD, HMGCR, HNMT, HPN, HS6ST1, HSD11B2, HSD17B2, HSD17B8, HSDL2, HYAL1, IDH2, IDI1, IMPA2,
ISOC2, ISYNA1, ITIH2, KHK, KLB, LCN15, LDHA, LDHD, LIPC, LSS, LYZ, MAT1A, METTL7A, MMAB, MMP11, MTHFD1, MTTP, NDUFA2, NEU4, NME4,
NPC1L1, NQO1, NTHL1, OAZ1, OSBPL3, PAFAH1B3, PAH, PAICS, PAPSS1, PCBP2, PCSK9, PCYOX1, PCYT2, PEBP1, PGAM1, PGM1, PKM, PLA2G12B,
PLA2G2A, PNPLA3, PPAP2B, PPP1CB, PPP1CC, PRLR, PROS1, PSME3, PYCRL, QPRT, RARRES2, RXRA, S100A4, SARDH, SCD, SDPR, SEC62,
SERPINA10, SERPINA4, SGSH, SHMT1, SHPK, SLC23A1, SLC25A10, SLC27A5, SLC2A2, SLC2A3, SOD1, SORD, SPTLC3, SQLE, ST3GAL6, STAR,
SULT1A1, SULT1A2, SULT2A1, TFPI, TM7SF2, TPI1, TST, TTPA, TTR, TYMS, UBE2I, UBE2T, UBR7, UGT2A3, UNG, USP18
DNA replication and
repair
ANLN, BLM, BRCA1, BRIP1, CDK1, CENPE, CENPF, CHAF1A, CHAF1B, CHEK1, CHEK2, CHTF18, DDB2, DUT, ESPL1, EXO1, FANCA, FANCD2, FANCG,
FANCM, FEN1, EN1, GINS1, GINS2, HMGB1, HMGB2, KIF11, KIF14, KIF15, KIF22, KIF23, KIF2C, KIFC1, LIG1, MCM2, MCM3, MCM4, MCM6, MCM7,
MCM8, MSH2, MSH6, NAP1L1, NASP, NEIL3, NEK2, NUDT1, ORC1, ORC6 (includes EG:23594), PBK, POLA1, POLA2, POLD1, PRC1, PRIM1, PTTG1,
PTTG2, PTTG3P, RAD51, RAD51AP1, RAD54L, RBBP4, RBM14, RECQL4, RFC2, RFC5, RNASEH2A, RPA1, RPA3, RRM1, RM2, SMC1A, SMC2, TK1,
TOP2A, TPX2, TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB4B, UHRF1
signal transduction ADRA2C, AGT, ANGPTL1, ANTXR1, ARRB1, ASB9, ASIC1, AXIN2, C5, C9orf86, CAPRIN1, CAPS, CIT, CKB, CLIC3, CORT, DCDC2, DEPDC1, DEPDC7,
DFNB31, DKK1, DOK6, DUSP9, ECT2, EDN1, EPO, ERBB2, FGFR4, FGG, FN3KRP, FZD2, FZD4, GIPC2, GPER, GPSM2, HBS1L, IFNGR1, IQGAP2, ITPR2,
KIAA1199, LBR, LGR4, MGST2, NDFIP2, NMB, NR2F2, NUDT4, OPN3, P2RY8, PAQR4, PAQR8, PAQR9, PASK, PCSK1N, PDGFRB, PIK3R3, PLEKHB1,
RAB15, RAB17, RABL2A, RACGAP1, RANBP1, RASSF4, REEP6, RHOBTB1, ROR1, RPS6KA3, RTKN2, SDC2, SFRP4, SLC9A3R1, SMO, SNX5, SPARC,
SSTR1, STMN1, STMN3, TAS1R1, TBC1D4, TGFBR3, TNS3, WDR77
transport A2M, ABCC6, AQP6, ASGR1, ATOX1, ATP1A3, ATP1B1, ATP2A2, ATP5D, ATP5G1, ATP5L, ATP6V0E2, CACNB4, CHDH, COPZ1, CP, CPLX2, CYB5A,
CYP27A1, CYP2W1, CYP4V2, DAO, DBI, EME1, FAM3B, FMO5, FXYD2, HPX, HSP90AA1, KCNJ10, KIF18A, KIF20A, KIF4A, LRP4, MBL2, MTCH2,
NDUFB7, NDUFC2, NDUFS5, NEDD4L, NHLRC2, PDZK1, PKDCC, RAB11FIP4, RBP5, RCN2, RHBG, RNFT2, SCN1A, SERPINA6, SFXN2, SLC13A3,
SLC13A5, SLC16A10, SLC1A2, SLC25A1, SLC25A23, SLC26A8, SLC2A1, SLC2A14, SLC2A9, SLC37A4, SLC46A1, SLC47A1, SLC6A12, SLCO2B1,
SLCO4C1, SORBS2, SORT1, STX10, SYTL2, TF, TFRC, TMED9, TTYH1, UQCR10, UQCRQ
cell cycle AURKA, AURKB, BCCIP, BIRC5, BUB1,, B1B, CCNA2, CCNB1, CCNB2, CCNE1, CCNE2, CDC20, CDC23, CDC25A, CDC25C, CDC45, CDC6, CDC7,
CDCA4, CDCA5, CDK2AP1, CDK6, CDKN2C, CDKN3, CDT1, CETN2, CKS2, E2F1, E2F2, E2F7, E2F8, ESCO2, GAS2L1, GAS2L3, GSG2, GTSE1, IGF2,
KANK1, KIF20B, KNTC1, MAD2L1, MAP2K6, MCM5, MKI67, MYBL2, NCAPD2, NCAPG, NCAPH, NDC80, NEDD9, PARD6G, PCNA, PKMYT1, PLK1,
PLK4, PTMA, PTP4A1, RECK, SEPT2, SEPT6, SESN1, SMC4, SPAG5, TCF19, TFDP1, TTK, UBE2C, ZWINT
regulation of
transcription
ASH1L, CREB3L3, DHX9, DLX4, DNMT1, ELL2, FOXA1, FOXJ1, G2E3, GATA4, GTF2I, HLF, HNRNPD, HOXA3, HOXD1, HSBP1, ID2, ILF3, IRX3, ISX,
KDM1A, MBD2, MED30, MEIS2, MIS18BP1, MYCBP, MYCN, NCOA4, NFE2, NR2F1, ONECUT1, PEG3, POLR2L, POU2AF1, RFX5, SALL2, SLC2A4RG,
SOX5, SOX9, SP100, SSBP4, TBX2, TCEA3, TCEB2, TCF3, TRIP13, TRMT5, WDHD1, ZNF107, ZNF124, ZNF286A, ZNF331, ZNF417/ZNF587
cell growth and
proliferation
ACTA2, BMP4, CALML4, CD320, CDC42EP4, CDCA2, CDCA7, CDCA8, CHPT1, CKAP2, CRIP1, CSRP2, CTGF, CTNNBIP1, DIAPH3, DZIP1, ENAH, FGD3,
FGFR3, FRAT2, FSCN1, GDF11, GJB1, GPC3, GPNMB, IFT81, IGF2, IGFBP7, IL17RB, ITM2B, KAZALD1, LAMC1, LGI1, LMNB2, NDRG2, NET1, NUF2,
PALMD, PCSK6, PDS5B, PMP22, RBBP7, SEMA6B, SERPINF1, ST6GAL1, STIL, SYNE2, TBC1D8, TDGF1P3, TMEM97, TNFRSF11A, VIL1
B. Genes upregulated in HepG2 cells
signal transduction ABR, ACAP2, ACVR1, ADAM17, ADCY7, AGFG1, AKAP12, AKAP13, ANKRD1, ANTXR2, ARHGEF2, ARL5B, ARL6, ARL8B, ARNTL2, ASAP2, ASB1, AXL,
BCAR3, BRAP, C5AR1, CACNA2D4, CBL, CDC42BPA, CDC42SE1, CREM, CRY1, CSNK1A1, CSNK1A1L, DFNA5, DVL1, DYNC1LI1, EPHA2, EPS15, F2RL1,
FEZ2, FHL2, FNTA, GABARAPL1, GCKR, GDF15, GDI1, GIT2, GKAP1, GNB4, GNB5, GOLGA5, GPRC5A, GPSM1, GRB10, GTPBP2, HBEGF, HOMER2,
HTR7, IFNAR1, IPO7, IQGAP1, ITGA6, ITGB1, ITPKA, ITPKC, JAK2, KLF10, LAT2, LY96, MPP1, MPP3, MPZL1, MYO9A, NCOA1, NFKBIB, P2RY2, PDE4D,
PDLIM7, PIK3CA, PKIB, PLAU, PLCD3, PLEKHG5, PLEKHM1, PMEPA1, PXK, RAB10, RAB21, RAB22A, RAB31, RAB39B, RAB3B, RAB43, RAB5A, RAB6A,
RAP2B, RASAL2, RASD1, RASGRF2, RASGRP3, RASSF8, RGCC, RGS20, RHOC, RHOD, RHOF, RHOQ, RIT1, RORA, RP9, RPAIN, RRAD, RRAS2, SH2B3,
SH2D5, SH3BP2, SH3KBP1, SHC2, SHOC2, SKIL, SMAD2, SNX16, SPRY4, SPSB1, SQSTM1, SRGAP1, STAM, STC2, TGM2, TICAM1, TNS1, TRIM23,
TULP3, ULK1, WASF2, WNT7B, WSB2, XPR1, ZNF259
metabolism ABHD5, ACSL5, AGPAT2, AGPAT9, AGPS, ALDH1L2, ALS2, AMPD3, AP3D1, APH1A, APOL6, AQP7, ARG2, ASNS, B3GNT3, BMS1, BPNT1, CCDC91,
COQ10B, CSGALNACT2, CSTA, CTH, CYP39A1, DAGLA, DDAH2, DHDH, DHRS7, FUT1, GBE1, GCLC, GCLM, GCNT3, GFPT1, GFPT2, GK, GNE, GOT1,
GSR, HK1, HKDC1, HMOX1, HSD17B1, HSDL1, IDH3A, IDS, INPP1, IRS2, KCMF1, KDM1B, KIAA0368, KYNU, LDLR, LGALS3, LOC286297, LPGAT1,
MIA3, MICAL2, MTHFD1L, MTHFD2, MUS81, NAGS, NCF2, NCOA7, NCOA7, NGLY1, OLAH, PFKP, PGM2L1, PGM3, PIP5K1A, PLCH2, PNPLA8, PPARG,
PPME1, PRKAB2, PRNP, PROSER1, PSAP, PTGR1, RBP1, SAMD8, SAT1, SERPINB8, SGMS2, SHMT2, SLC20A1, SLC25A27, SLC3A2, SMG1, SMPDL3A,
SPTLC1, SRXN1, TBRG1, TMEM54, TNKS, TPMT, TSPAN7, UGT2B4, UPP1, USP32P2, USP36, VIMP, VLDLR, YME1L1
regulation of
transcription
AFF4, ATF3, ATF4, BATF, BHLHE40, CEBPB, CEBPE, CEBPG, CREB5, CREBRF, DENND4A, DOPEY2, EGR1, ELF1, ELF2, ELL2, ETV5, FOXC1, FOXK2,
FOXP1, GATAD1, GTF2E2, HBP1, HDAC4, HES5, HINFP, HIVEP2, IRF9, JHDM1D, JUN, KLF2, KLF5, LONRF1, LRRFIP1, MAFF, MAFG, MAFK, MBD1,
MED18, MED8, MYCL1, MYNN, NFXL1, NPAS2, NR1D2, NRBF2, PHF20L1, POLR3C, PRDM4, RELB, SERTAD2, SMAD3, SOX4, SP100, SP110, TAF1A,
TCEA1, TCF20, TMF1, TRIP4, ZBTB43, ZBTB6, ZBTB8A, ZFHX2, ZKSCAN5, ZMYM6, ZNF146, ZNF165, ZNF222, ZNF25, ZNF251, ZNF26, ZNF264,
ZNF274, ZNF276, ZNF277, ZNF319, ZNF33B, ZNF354A, ZNF37A, ZNF426, ZNF432, ZNF449, ZNF473, ZNF562, ZNF568, ZNF583, ZNF585B, ZNF641,
ZNF643, ZNF655, ZNF673, ZNF777, ZNFX1, ZSCAN29
transport ABCA4, ABCB1, ABCC2, AP4S1, AQP3, ARFGAP3, ATP11B, ATP2A3, ATP6V0A2, ATP6V0D2, ATP6V1D, BET1, CLIC1, COL16A1, CTHRC1, CYP4V2,
DNAJC10, ERO1LB, FNBP1L, FTH1, GLRX3, ITPR3, ITSN2, KCNMB3, KCTD11, KCTD9, KPNA4, LCN2, LOC494141, LRP10, LYRM7, MT1X, MT2A,
MYO5A, NUPL1, PARP4, PDIA2, PITPNC1, PYROXD1, RABGEF1, SEC14L1, SEC24D, SLC12A6, SLC16A5, SLC16A6, SLC22A15, SLC22A18, SLC22A4,
SLC25A25, SLC25A36, SLC25A51, SLC26A11, SLC30A7, SLC33A1, SLC38A1, SLC41A2, SLC4A7, SLC9A1, SMOX, SPNS2, SQRDL, SSR3, STAM2,
STX1A, STX3, STX4, TARS, TMCO3, TMEM184A, TMX3, TRAPPC6B, TRPC1, TRPV2, TUSC3, TXNRD1, UNC13D, VTI1A, XPOT, YKT6
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Table 2. Cont.
cell death AIFM2, BAX, BBC3, BCL10, BCL2A1, BCL2L1, BTG1, CARD10, CDKN1A, CDKN2B, CSRNP2, ELMOD2, ERN1, F2R, GADD45A, GADD45B, GLRX2,
GULP1, HRK, IER3, IGFBP3, LGALS1, LGALS7/LGALS7B, MCL1, MDM4, NLRC4, PAK1, PAWR, PDCD6IP, PHLDA2, PPARD, PPP1R15A, PRKCZ, RIPK2,
RRAGC, SH3GLB1, STK17A, STK4, TAX1BP1, TNFRSF10B, TNFRSF12A, TNFRSF25, TRIB3, UNC5B, VHL, XIAP, YARS, ZAK
cell growth and
proliferation
AREG/AREGB, BCAT1, BLZF1, BMP6, BTG3, CDC37L1, CDKN2B, CDV3, CYR61, DYNC1H1, DYNC1I2, EREG, HIP1R, IGFBP1, IL11, ISG20, ITCH, KIF26B,
KIF27, KIF3C, KLF6, LAMP3, MET, MXD1, PAFAH1B1, QSOX1, RAD50, S100A11, S100A6, SERTAD1, SFN, SOCS6, SOCS7, SPEG, TEP1, TIMP1, TRIB1,
TSPYL2, TUBB2B, TUBB6, VEGFA, WHSC1L1
C. Genes downregulated in Huh7 cells
metabolism AADAC, ACAT2, ACLY, ACMSD, ACSL3, ACSL4, ACSL6, ACSS2, ACSS3,. ACY1, ADAMTS9, AGMAT, AGMO, AGPAT1, AGXT, AHCYL1, AK2, AK4,
AKR1B1, AKR1B10, AKR1C1/AKR1C2, ALDH1A1, ALDH3A2, ALDH5A1, ALDOC, ALG8, AMT, ANGPTL3, ANKRD36, ANKRD36C, ANXA4, APOA1,
APOB, APOC3, APOM, ARG1, AS3MT, ASF1A, ASL, ASRGL1, ATAD2, ATP11A, ATP1A1, ATP2A2, ATPIF1, AZGP1, B3GNT1, BCKDHB, BDH2, BPGM,
BTD, C14orf126, CAT, CBR1, CEBPA, CHST6, CHST9, CMPK1, CPM, CTPS1, CYP51A1, DDAH1, DHCR24, DHCR7, DHFR, DHFRL1, DHX9, DPYD,
DPYSL2, EBP, ELOVL2, ENOSF1, ENPP3, EPT1, EXTL2, F13B, FABP1, FABP5, FADS2, FANCM, FDFT1, FDPS, GATM, GBE1, GCLM, GCNT1, GCSH, GDA,
GGH, GLDC, GLO1, GLUD1, GLUD2, GPAM, GPT2, GSR, GSTA1, GSTA2, GSTA5, GSTM3, GSTT2/GSTT2B, GUSBP4, HELLS, HGD, HIBCH, HMGCR,
HMGCS1, HMGN1, HMGN3, HNF4A, HP, HPRT1, HS2ST1, HSD11B2, HSD17B12, HSD17B2, IDH1, IDI1, IQCD, ITIH2, KLB, LDHA, LDHB, LGSN, LIPA,
LOXL4, LPGAT1, LRP8, LSS, LYZ, MAN1A1, MAT2A, ME1, MGST1, MINPP1, MMD, MMP15, MOGS, MRI1, MTTP, NEDD8, NME4, NQO1, NR1H4,
NR2F2, NT5E, OSBPL3, PAICS, PCBP2, PCSK9, PDK1, PFKFB3, PFKFB4, PGAM1, PGK1, PHKA2, PIGZ, PITPNA, PKM, PLD1,, PLOD2, PNPLA3, PNPLA4,
PPP1CB, PRMT6, PROS1, PRTFDC1, PSAT1, PTDSS1, PYCRL, RDH11, RDH5, RDM1, SCD, SERPINA3, SETBP1, SHMT1, SIGMAR1, SLC23A1, SLC27A2,
SLC6A14, SLC6A6, SLPI, SMA4, SOD1, SORD, SPINK4, SPTLC3, SQLE, ST3GAL5, SULT1A1, SULT1A2, TDO2, TFPI, TM7SF2, TMEM41B, TPI1, TPI1P2,
TST, TTN, TYMS, UCHL1, UCP3, UGT2B10, UGT2B11, UGT2B17, UGT2B4, VNN2, VNN3, ZNF407
signal transduction ABAT, ADAM9, AES, AGTR1, AHSG, AKAP9, ARL5A, ASAP2, ASIC1, BBS4, C5, C9orf86, CALM1, CAMKK2, CD247, CD83, CIT, CKB, COCH, CREB1,
CRYZ, CSNK1A1, CSNK1G2, DEK, DKK1, DKK3, DLGAP5, DOCK8, DPYSL5, ECT2, EDN1, EPAS1, EPO, ERBB3, F2RL2, FZD1, FZD4, FZD7, GNA12,
GNL3L, GPR161, GPR20, GPR98, GTF2I, HCAR3, HOMER1, IL13RA1, IL22RA1, IP6K2, KITLG, LANCL1, LENG8, LIMD1, LPAR1, LPAR6, LPHN2, MGST2,
NDFIP2, NPTN, NR2F1, NRTN, OGT, P2RY6, PDE7A, PDGFRB, PGRMC1, PIAS2, PIK3R3, PLEKHB1, PROM1, RAB11A, RAB37, RABL2A, RAPGEF6,
RASSF7, RHOBTB3, RTKN2, S1PR1, SAR1A, SDC1, SDC2, SH2B3, SH3KBP1, SHANK2, SMO, SNX10, SPA17, SPRY2, SPRY4, SRGAP1, SSTR2, STMN1,
STMN3, STXBP4, TAS2R45, TBC1D1, TLE2, TXNRD1, TYRO3, WDR77, WNK4, YWHAB
cell growth and
proliferation
ACTB, ADAM18, ADAM23, ADAM28, ADD3, AEBP1, AKR1C3, ANLN, ANXA13, ASPH, BCAT1, CAPZA1, CDCA7, CNN3, CSRP2, CTNNBIP1, DMD,
DNAH5, EML4, EMP2, EPB41L5, FADS1, FGA, FGFR3, GDF11, GHR, GLCE, H2AFX, H3F3A/H3F3B, HIST1H1A, HIST1H2BN, HP1BP3, ITGA2, JAG1,
KIF14, KIF20A, KIF24, KIF9, LAMC1, LIMCH1, LMLN, LMNB2, MESDC2, MSL3, MYH2, MYH4, NASP, NRP1, NUDT6, PAFAH1B1, PALMD, PDLIM5,
PDZK1, PFN2, PKD2, PRDX1, PRG4, RBBP7, RPS6KA3, SMARCC2, SOX9, SPRY1, SRI, ST6GAL1, TARDBP, TBC1D8, TGFBR2, TMEM97, TMSB10/
TMSB4X, TNNC1, TNNI2, TPM1, TPM3, TPX2, TUBA1B, TUBA1C, TUBB4B, TXN, WASF1
regulation of
transcription
ARID5B, BCOR, BOLA3, CBFB, CNOT6, CUX2, EGR1, ELL2, ETV1, ETV4, ETV5, EZH2, FOS, FOXA1, FOXN4, GCFC1, GTF3C2, HEXIM1, HHEX, HMGA2,
HMGN2, HNF1B, HNRNPD, HSBP1, ID1, ID2, ID3, JDP2, KLF12, LOC100129387, MBD2, MECOM, MECP2, MED31, MEIS2, MYB, MYCBP, NFE2L3,
ONECUT1, ONECUT2, PAPOLA, PIR, PLAGL2, PNRC2, POLR2L, PRDM10, PSIP1, PTRF, RFX2, RFX5, SALL2, SALL4, SCML2, SMAD6, SP100, SUB1,
TAF15, TCF3, TH1L, VGLL3, WHSC1, ZBTB20, ZMYM2, ZMYND8, ZNF107, ZNF207, ZNF257, ZNF281, ZNF286A, ZNF331, ZNF551, ZNF789, ZSCAN5A
transport A2M, ABCB6, ABCC2, AP1M2, AP2A2, AQP10, ATP1B1, CCDC14, COL4A5, COL5A2, COL9A3, COPZ1, CP, CYP26B1, CYP4F11, CYTB, DBI, DNM1L,
ETFB, GC, GA1, GJA1, GJB2, HIATL1, KCNE3, LRP10, LYRM7, ND3, ND5, NDUFC2, NHLRC2, NUP50, RAB8B, RBP4, RNF144B, RPGR, SCARA3, SEH1L,
SERPINA6, SFXN2, SLC12A2, SLC13A5, SLC16A10, SLC16A3, SLC18B1, SLC19A3, SLC1A1, SLC1A3, SLC22A9, SLC26A10, SLC2A9, SLC36A4,
SLC39A4, SLC40A1, SLC44A1, SLC47A1, SLC4A4, SLC7A11, SLCO1B1, SLCO1B3, SLCO2B1, SORCS2, SYT12, TF, TFRC, TXNDC12, UQCR11, VDAC1,
VPS13A
cell cycle ASPM, BCCIP, BUB1B, CCNB1, CCND1, CCNE1, CCNE2, CDC23, CDC45, CDCA3, CDK6, CDKN2A, CETN2, DST, DUSP6, E2F2, E2F7, E2F8, ESCO2,
ESPL1, FGF5, IL8, KIF11, KIF23, KNTC1, MCM5, MKI67, MPHOSPH6, NCAPD2, NCAPG, PARD6G, PCNA, PPP1R9B, PSMD1, PTMA, RAN, RBL2, RECK,
RGCC, SEPT10, SEPT2, SKP2, SMC4, TCF19, TFDP1, TGFB1, UBE2C, ZWINT
DNA replication and
repair
BLM, BRCA1, BRIP1, CDC6, CDC7, CDK2AP1, CENPE, CENPF, CTGF, CXCL6, DNMT3B, DUT, FANCA, FANCL, GINS1, GINS2, GTSE1, HMGB1, LIG1,
MCM3, MCM4, MCM6, MSH2, MSH5, MSH6, NAP1L1, ORC6, PARP1, POLA1, POLD3, POLQ, PRIM1, PRKDC, PTTG1, PTTG2, RAD51AP1, RBBP4,
RBM14, RBMS1, RPA1, RRM2, SMC1A, TK1, TOP2A, UHRF1, UNG
D. Genes upregulated in Huh7 cells
regulation of
transcription
ADNP2, AFF4, AKAP17A, ALX1, ATF3, BACH2, BATF, BATF3, BAZ2B, BRD1, BRF1, BUD31, C21orf7, CEBPG, CIR1, CITED4, CREB3, CREB5, CREBRF,
CRTC1, DEAF1, DGCR6L, DLX2, DNAJC1, DUX4, ELF3, ETV6, EYA4, FOXC1, FOXK2, GABPB1, GATA5, GLI1, GTF2IRD1, GZF1, HBP1, HCFC2, HDAC4,
HES4, HES7, HINFP, HIVEP2, HLF, HNF1A, HOXA5, HOXB7, HOXC12, HSF1, INTS12, IRF4, IRF5, IRX3, JUN, KLF13, KLF15, KLF16, KLF6, KLF7, LBX1,
MAF, MAFB, MAFF, MAFK, MAX, MED15, MED16, MED8, MESP1, MLLT10, MPPED1, MSX1, MYNN, NEUROG3, NFIL3, NFKBIB, NFKBIE, NFKBIL1,
NFXL1, NKX2-1, NPAS1, NPAS3, NR1D1, NR1D2, NR2E1, NR3C1, NR3C2, PER1, PHF14, PHF15,m PHF2, PHOX2A, POLR3C, POU3F3, PRDM16,
PRDM4, RARA, RARB, RCOR3, RELB, RERE, RFX3, RLIM, RNF14, RORA, RRN3P1, SIRT7, SIX4, SMAD2, SMARCA2, SOX3, SP1, SP100, SP110, SP140,
SP5, SQSTM1, SREBF2, STAT5A, STAT5B, TBX15, TBX19, TCF20, TEF, TIGD7, TMF1, TRIP4, YAF2, ZBTB10, ZBTB16, ZBTB2, ZBTB25, ZBTB38, ZBTB40,
ZBTB43, ZBTB8A, ZNF140, ZNF165, ZNF177, ZNF193, ZNF197, ZNF22, ZNF235, ZNF238, ZNF251, ZNF256, ZNF26, ZNF264, ZNF274, ZNF276,
ZNF292, ZNF295, ZNF319, ZNF333, ZNF33B, ZNF350, ZNF354B,. ZNF408, ZNF449, ZNF461, ZNF473, ZNF550, ZNF555, ZNF568, ZNF571, ZNF581,
ZNF585A, ZNF586, ZNF593, ZNF610, ZNF623, ZNF624, ZNF641, ZNF669, ZNF673, ZNF70, ZNF707, ZNF777, ZNF79, ZSCAN10, ZSCAN29
transport ABCA3, ABCA7, ABCB7, AFTPH, AP2B1, AP3S2, APBA3, APOBEC3D, ARL1, ARL5B, ARL8B, ATP6V0A2, ATP6V0D2, ATP6V1B1, ATP6V1C1, ATP6V1D,
ATP6V1E1, ATP6V1F, ATP6V1H, BET1, C7orf13, CACNA1I, CASC3, CATSPER3, CHRNA3, CLCN5, CLCN7, COG3, COL16A1, COX6A2, CTNS, CYP4V2,
CYTH3, DDX19B, DSCR3, EEA1, ERO1L, ERO1LB, EXOC3, EXOC4, FABP3, FAM129A, FDX1L, FLVCR2, FNBP1L, FOLR3, GLDN, GOSR1, GRIA3, GRID1,
GRIN2D, ICA1, IGF2R, IPO7, ITPR3, ITSN2, KCMF1, KCNE2, KCNMB3, KCTD18, KDELR2, KPNA4, LIN7C, LMAN1, LOC440354, LOC494141, MAGT1,
MCF2L, MCOLN3, MT1X, MYO5A, NAPG, NEDD4L, NOX4, NRP2, NUDT9, NUP93, OXNAD1, PEA15, PYROXD1, RAB11FIP4, RAB17, RAB21, RAB22A,
RAB33B, RAB39B, RAB40C, RAB43, RAB6A, RAB9A, RALBP1, RAMP1, RANBP3, RFESD, RHCG, RHOQ, RILP, RNF216, RRAGD, SAR1A, SCG5, SEC14L1,
SEC22A, SLC12A7, SLC15A4, SLC16A14, SLC16A6, SLC19A2, SLC22A15, SLC22A3, SLC25A12, SLC25A13, SLC25A25, SLC25A29, SLC25A33,
SLC25A36, SLC25A38, SLC25A51, SLC26A1, SLC26A11, SLC2A14, SLC30A2, SLC33A1, SLC41A2, SLC47A2, SLC6A12, SLC9A1, SLCO1A2, SNX12,
SNX8, SPNS1, STAM2, STOML1, STX18, STX1A, STX3, SYT11, SYTL2, SYTL3, TAP1, TIMM44, TMCO3, TMEM184A, TOM1, TPCN2, TRAPPC6B, TRPV2,
TUSC3, USE1, VPS11, VPS26B, VPS41, VTI1A, YKT6, ZFYVE1
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Validation of Microarray Findings with Semi-quantitative
RT-PCR (sqRT-PCR) and Quantitative RT-PCR (qRT-PCR)
To validate our microarray results, we arbitrarily selected 13
differentially-expressed genes following combination treatment.
Some of these genes were previously reported to be affected by
sorafenib and by celecoxib and are involved in the regulation of
apoptosis, ER stress response, DNA damage response, cell
proliferation and invasion. These genes included BIRC5 (survivin),
Cyclin D1 (CCND1), Harakiri (Hrk), DNA-damage-inducible
transcription factor 3 (DDIT3, also known as GADD153 or
CHOP), Tribbles-related protein 3 (TRIB3, also known as TRB3),
metallothionein 2A (MT2A), La ribonucleoprotein domain family
member 6 (LARP6), Yes-associated protein 1 (YAP1), Fatty acid-
binding protein 1 (FABP1, also known as liver-type fatty acid-
binding protein, L-FABP), and Dickkopf 1(DKK1). In addition,
expression of some other genes recently reported to be involved in
hepatocarcinogenesis, such as Klotho-beta (KLB), fibroblast
growth factor 19 (FGF19), fibronectin type III domain-containing
3B (FNDC3B), was also analyzed. Gene expression was quantified
by sqRT-PCR and in some cases by qRT-PCR in control and in
treated cells. sqRT-PCR and qRT-PCR analyses were performed
in samples previously used for the microarray experiments then
repeated using RNA extracted from two other different experi-
ments. Table 3 shows the gene expression measurements of all the
validated genes.
Validation of Microarray Findings with Western Blotting
Microarray data showed that the gene encoding for survivin
(BIRC5) was significantly down-regulated in HepG2 cells upon
treatment with combination compared with the single agent. As
shown in Figure 8, we validated this observation in both cell lines
at the protein level. An intriguing result observed in the
microarray analysis and also validated by qPCR was that the
expression of the gene encoding a member of the Dickkopf (DKK)
family proteins, DKK1, was inhibited by celecoxib and sorafenib
alone, and the combined treatment further increased this effect
(Table 3), resulting in a greater inhibition of mRNA expression
levels than when either inhibitor was used alone. As shown in
Figure 8, we also confirmed this observation at the protein level by
Western blotting, confirming that the combination treatment
synergistically inhibited the expression of DKK1 in HepG2 and
Huh7 cells.
In our screening, we observed increased YAP1 gene expression
in HepG2 cells upon SOR or CLX treatment which was further
potentiated following combination treatment. Similarly, the
combination treatment increased YAP1 protein expression more
than each agent used alone (Figure 8).
Microarray results showed that the ER stress response genes
DDIT3/CHOP and TRIB3 were significantly up-regulated upon
combination treatment in HepG2 cells, whereas in Huh7 cells,
only the DDIT3/CHOP gene was synergistically up-regulated by
the combination treatment (Table 3). As shown in Figure 8, these
observations were also confirmed at the protein level.
Discussion
HCC is a complex disease which needs interacting approaches
for effective therapy. A multi-targeting-based approach is of
particular relevance in HCC treatment, thus combination therapy
would be more appropriate and may increase therapeutic efficacy.
Given that sorafenib is the standard of care in the first-line setting
for advanced HCC patients, the new agents and new drug
combinations must be compared head-to-head with sorafenib.
However, to our knowledge, there are few data examining in detail
the effects of sorafenib in combination with other anti-cancer
drugs in HCC. Therefore, to inhibit multiple signaling pathways
involved in HCC, in the present study we investigated whether in
two human HCC cell lines, HepG2 and Huh7, the combinations
of SOR+CLX have more potent antitumor effects than sorafenib
alone. In addition, we also examined the changes in the
Table 2. Cont.
metabolism ACADS, ACBD3, ACOX1, AGPAT3, AHCYL2, ALAD, AMACR, ANXA1, AP3D1, AQP7, ARG2, ARPP19, ARSE, ASAH1, ATE1, AUH, B3GALT6, C5orf4,
CA5B, CCDC91, CEBPA, CEPT1, CHKA, CHST3, COQ10B, COQ7, CORO2A, CPT1A, CTH, CYP3A4, CYP3A5, CYP3A7, DAGLA, DAGLB, DHDDS, DHRS2,
DHRS3, DIP2B, DIP2C, DMGDH, DPH5, FA2H, FAM59A, FUT3, GALT, GDPD3, GFPT1, GFPT2, GLI4, GNPDA1, GPD1L, GPR56, HELQ, HEXB, HEXDC,
HKDC1, HNMT, HS2ST1, HS3ST1, HSD17B1, HSD17B14, HSDL1, IDS, INSR, IRS2, KDSR, LEP, LGALS2, LGALS8, LGALSL, LIPT1, MANBA, MCCC2, ME3,
MRPL43, MT1A, MT1B, MT1E, MT1F, MT1G, MT1M, MTHFR, NADK, NAGK, NEU1, NMNAT3, NSMAF, OAT, OGDHL, OSBPL2, OSBPL6, P4HA3, PAPLN,
PCCA, PDE8B, PDPR, PFKFB3, PGM2L1, PGM3, PIP4K2A, PLA1A, PLA2G4C, PLAG1, PLCG2, PLD6, PNPLA8, PPARGC1A, PPARGC1B, PRKAB2, PRNP,
PTGES, PYGB, PYGM, RDH13, RNH1, SAMD8, SAT1, SAT2, SCAP, SDSL, SERPINB9, SETDB2, SGPL1, SLC20A1, SLC3A1, SLC3A2, SMPDL3A, SOAT2,
SPINK1, SPINK6, SPINT1, SPTLC1, SPTLC2, STBD1, SULF2, SULT1C2, TBCE, TBRG1, TGM1, TMLHE, UAP1L1, UGCG, UPP1, USP32P2, USP36, USP54,
XRN1, XYLB
signal transduction ABL2, ACAP3, ADCY9, AGAP3, AGFG1, AHRR, AKAP12, AKAP13, AKAP8L, ANGPT2, ANKRD1, ANXA3, ARHGAP25, ARNT2, ARRB2, ASAP2, ASB6,
BAIAP2L1, BCR, BDKRB1, BDKRB2, BRAP, C5AR1, CALCB, CAMLG, CASKIN1, CBL, CCL4, CKMT1A/CKMT1B, CMTM1, CNIH3, CNKSR3, CREBBP,
CTAGE1, CXCL12, CXCR7, DNAJC27, DOCK11, DOCK6, DTNA, DTNBP1, DUSP10, DVL1, ERBB3, F2RL1, GABARAPL1, GDF1, GDF15, GIMAP2, GIT2,
GKAP1, GNA13, GNAZ, GNB5, GNG12, GNG2, GNGT1, GNL1, GOLGA5, GPR146, GPR150, GPR153, GPR157, GPR35, GPSM1, GRASP, GRB10, GTPBP2,
GUF1, HS1BP3, IFRD1, IGBP1, IGFALS, IP6K1, JAK1, KLC1, LPHN3, LPXN, MAPK14, MED13L, MKNK2, MLLT4, MPP1, MYO9A, MYO9B, NPFFR2, NPPC,
OXTR, PDE1A, PINK1, PKN1, PPARGC1A, PPM1A, PRKACB, PSEN2, PTPRJ, PVR, RAB32, RALGAPA1, RALGDS, RAP1GAP, RASA4/RASA4B, RASSF5,
RASSF6, RASSF8, RCAN3, RGS16, RHOBTB1, RHOU, RRAD, SAV1, SEC11C, SEL1L, SFRP4, SH2D3C, SHC2, SLC44A2, SMURF1, SNX16, SPPL3, SPSB2,
SPSB3, SRPRB, SSR3, SWAP70, TAOK3, TBC1D15, TBC1D3, TEC, TRAF6, TRIM23, TRIP6, VAC14, VIMP, WDSUB1, WNT6, XCL1
cell growth and
proliferation
ABI1, ABLIM3, ABTB2, ANAPC1/LOC100286979, APBB2, AREG/AREGB, ARHGEF2, BHLHE41, BIN1, BMP4, BMP8A, BTG1, BTG3, CABLES1, CAPN1,
CAV1, CCNG2, CDC42EP5, CDV3, CEP250, CGRRF1, CHRDL2, CLIP1, CLK1, CNN1, DAAM1, DLEC1, DMAP1, EFEMP1, EGFR, EMD, EPB41, EPC1, EREG,
EZR, FHOD3, FZR1, GFER, GRN, H1F0, HDAC5, HDAC9, HIST1H2AB/HIST1H2AE, IGFBP1, IGFBP6, ISG20, ITCH, JAK2, JMJD6, KAT5, KLF11, LF4,
KRT16, LAD1, LAMP3, LOC100233156, LRCH4, LTBP1, MAP2, MAPRE2, MRAS, MVP, MXD1, MYH6, NAMPT, NDRG4, NEBL, NEK1, NOV, NPM2, NPR3,
NRG1, NSFL1C, NTN4, OSGIN2, PAFAH1B1, PARD3B, PARD6G, PHF17, PRPH, PTHLH, S100A6, SDCBP, SEMA3D, SMPX, SOCS2, SPAG9, SYNE1, TAF1,
TAF1L, TEKT4, TLK2, TMOD1, TRIB1, TUBB2B, TUBGCP3, TUFT1, TXNL4B, VAT1, VILL, VIM, WHSC1L1, WISP3, ZEB1, ZNF259
cell death AXIN1, BBC3, BCL2L11, BFAR, BIK, BIRC3, BIRC7, CARD10, CARD14, CDK11A/CDK11B, CIDECP, CSRNP1, DAPK2, DAPK3, ELMO2, ELMOD2, EMP3,
FEM1B, FOSL2, GADD45A, GADD45B, GADD45G, GDNF, HRK, IFIH1, IGFBP3, IL18, IP6K3, MDM4, MTL5, MX1, NRG2, NUPR1, PAK1, PAWR, PDCD4,
PPP1R13B, PPP1R15A, PRKCZ, RIPK2, RRAGC, SEMA6A, SH3GLB1, TNFRSF10B, NFRSF14, TNFRSF9, TRIB3, TRIM35, VEGFA, XIAP
doi:10.1371/journal.pone.0065569.t002
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transcriptional profiles for both HCC cell lines upon combined
SOR+CLX treatment.
Our data showed that each inhibitor alone can reduce cell
growth; however the SOR+CLX combination displayed a
synergistic effect in terms of cell growth inhibition and apoptosis
induction. Transcriptomic analysis identified a number of genes
that were commonly differentially expressed in both the HCC cell
lines, as well as alterations in gene expression patterns that were
specific for each cell line. Indeed, clustering analysis based on the
selected 174 genes which were expressed differently in the HepG2
and Huh7 cells revealed the formation of two major cluster groups
that clearly distinguish HepG2 and Huh7 cells upon SOR+CLX
treatment. This is to be expected, since apart from disparities in
Raf/MEK/ERK activity [23] and in COX-2 expression levels
[21], the two HCC cell lines also display other significant
differences, such as alterations in b-catenin, K-Ras, p16ink, p53,
p21, FANCD2 and other genes. These data are also in agreement
with our previous findings about the different molecular mecha-
nisms of cytotoxic action of celecoxib or sorafenib in HepG2 and
Huh7 cells [21,23]. Some genes, involved in the regulation of
apoptosis, ER stress response, DNA damage response, cell
proliferation and invasion (including BIRC5, Hrk, DDIT3/
CHOP, TRB3, CCND1, MT2A, LARP6, YAP1, FABP1, and
DKK1) were previously reported to be affected by CLX and by
SOR when applied alone [21,23]. These genes were now shown to
be synergistically modulated upon combination treatment, sug-
gesting their possible role in the enhanced antitumor effects
observed when cells were subjected to combined SOR+CLX
treatment.
In particular, HRK also known as death protein 5 (dp5), is a
pro-apoptotic mitochondrial protein of the Bcl-2 family and
induces cell death through interaction with death-repressor
proteins Bcl-2 and Bcl-X(L) [24]. HRK overexpression has been
shown to be linked to ER-stress response, induction of apoptosis,
inhibition of cell growth in vitro and in nude mouse xenograft
models [25–27]. On the contrary, inactivation of HRK expression
Figure 4. Comparison of common and distinct gene expressions across the various differentially- expressed gene groups in HepG2
and Huh7 cells upon celecoxib and sorafenib treatment. (A) Venn diagram analyses of genes, differentially expressed ($2-fold) in HepG2 and
Huh7 cell lines upon CLX (50 mM) treatment, SOR (7.5 mM) treatment, and combined SOR+CLX treatment. (B) Venn diagram comparison of common
and distinct genes uniquely modulated ($2-fold) in HepG2 and Huh7 cells only following combined SOR+CLX treatment. (C) Hierarchical clustering
based on the 174 genes list (2-fold difference in gene expression; p-value cutoff of 0.05) which discriminates HepG2 and Huh7 cells according to their
response to combined SOR+CLX treatment. Red signifies up-regulation and green signifies down-regulation.
doi:10.1371/journal.pone.0065569.g004
Figure 5. IPA functional pathway analyses of genes differentially expressed ($2-fold) in HepG2 and Huh7 cell lines upon combined
SOR+CLX treatment.
doi:10.1371/journal.pone.0065569.g005
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by promoter hypermethylation contributes to the development
and progression of various human cancers [28,29]. Our findings
demonstrated that sorafenib synergized with celecoxib in increas-
ing HRK expression in HCC cells and this was associated with an
inhibition of cell viability. However, the precise role of HRK in
HCC remains to be determined.
Figure 6. Network analysis of dynamic gene expression in HepG2 cells based on the 2-fold common gene expression lists obtained
following combined SOR+CLX treatment. The four top-scoring networks have been merged and are displayed graphically as nodes (genes/gene
products) and edges (the biological relationships between the nodes). Intensity of the node color indicates the degree of up- (red) or down (green)-
regulation. Nodes are displayed using various shapes that represent the functional class of the gene product (square = cytokine; vertical
oval = transmembrane receptor; rectangle = nuclear receptor; diamond=enzyme; rhomboid= transporter; hexagon= translation factor; horizontal
oval = transcription factor; circle = other). Edges are displayed with various labels that describe the nature of the relationship between the nodes: –
binding only,R acts on. The length of an edge reflects the evidence supporting that node-to-node relationship and edges supported by articles from
the literature are shorter. Dotted edges represent indirect interaction.
doi:10.1371/journal.pone.0065569.g006
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TRB3 has been identified as a novel target of CHOP in ER
stress response, and it seems to be involved in CHOP-dependent
cell death as a second messenger [30]. Studies indicate that TRB3
is functionally implicated in different biological processes, includ-
ing insulin resistance (IR), and the regulation of cell growth and
differentiation. However, its role in apoptosis is controversial. In
certain conditions endogenous TRB3 can act as a pro-apoptotic or
as a pro-survival protein. Our results demonstrated that
SOR+CLX synergistically promote CHOP mRNA and protein
induction in both HCC cell lines, whereas TRB3 mRNA and
protein were synergistically up-regulated by combination treat-
ment in HepG2 cells only. The precise role of these proteins in the
antitumor effects of the combination remains to be determined.
YAP1, the downstream effector of the Hippo kinase pathway, is
a key regulator of organ size and a candidate human oncogene.
The oncogenic roles of YAP have been shown in various types of
human malignancies [31–34], including HCC [35]. More than
50% of human HCCs show aberrant overexpression and nuclear
localization of YAP [36]. In HCC, YAP has been shown to be an
independent prognostic marker for disease-free and overall
survival [35]. On the other hand, anti-proliferative or pro-
apoptosis functions of YAP have been also demonstrated in the
context of DNA damage or cell stress, which induces binding of
Figure 7. Network analysis of dynamic gene expression in Huh7 cells based on the 2-fold common gene expression lists obtained
following combined SOR+CLX treatment. The four top-scoring networks have been merged and are displayed graphically as nodes (genes/gene
products) and edges (the biological relationships between the nodes). Figure legends are as described in Figure 6.
doi:10.1371/journal.pone.0065569.g007
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YAP with other transcription factors such as p73, a paralog of p53
tumor suppressor [37–39]. The functional activity of YAP protein
greatly depends on its localization and interaction with different
proteins [40,41]. Thereby, YAP regulation and cell context might
have a pivotal role in the choice of its partners and consequently
on the final and different outcomes, i.e. proliferation/transforma-
tion or death/tumor suppression [40,41]. In our screening, we
observed increased YAP gene expression in HepG2 cells on
treatment with a single agent and further enhancement of its
expression upon combination treatment. Therefore, additional
studies are necessary to clarify the role of the YAP protein in HCC
cells.
Of particular significance are our observations on DKK1
mRNA and protein expression after combination treatment.
Although the members of the DKK family normally act as
secreted Wnt antagonists and therefore should suppress Wnt-
induced tumor growth, DKK1 has been shown to be overex-
pressed in HCC tumor tissues. Its expression has been associated
with a poor prognosis in HCC patients [42]. These observations
suggest that DKK1 probably acts as HCC oncogenic factor, rather
than as a tumor suppressor, targeting the Wnt signaling pathway.
It is interesting to note that the DKK1 gene was one of the major
genes inhibited in both HCC cell lines after treatment with the
SOR+CLX combination. This result, although surprising, is
interesting for its clinical implications, since DKK1 may be a
good molecular marker of response to sorafenib treatment, or
other targeted therapies.
Several genes previously implicated in liver cancer were
discovered by our screening, including KLB, FGF19, FNDC3
and CCND1. The FGF19-FGF receptor 4 (FGFR4) signaling axis
has been implicated in the development of HCC in humans [43–
47]. Of interest in the study of Miura et al. [45] are the
observations that tumor FGF19 mRNA expression was an
independent prognostic factor for overall and disease-free survival,
and moreover, serum FGF19 levels significantly decreased in
HCC patients after curative hepatectomy. The sensitivity of serum
FGF19 thus makes it a promising tumor marker for HCC.
Therefore, our in vitro findings of sorafenib- and SOR+CLX-
mediated down-regulation of FGF19 mRNA in Huh7 cells
indirectly suggest that FGF19 could be potentially used in HCC
patients as a serum biomarker for monitoring the effects of
sorafenib, and possibly other treatments.
An intriguing observation is the fact that FGF19 is co-amplified
and co-overexpressed with CCDN1 in HCC [46]. In our
screening, we observed that CCND1 expression was reduced by
sorafenib alone and increasingly more by SOR+CLX treatment
Table 3. Fold expression of validated genes after treatment for 48 h with CLX (50 mM) and SOR (7.5 mM) either alone or in
combination.
A. HepG2 cells
Gene CLX SOR SOR+CLX
microarray RT-PCR Q-PCR microarray RT-PCR Q-PCR microarray RT-PCR Q-PCR
LARP6 2.38 2.760.3 8.70 6.060.1 27.06 9.060.7
HRK 2.44 3.860.2 2.70 7.260.6 9.16 19.060.5
BIRC5 22.560.3 22.39 210.060.1 216.34 25.060.3
YAP1 5.58 1.360.7 4.60 1.260.1 6.50 1.360.2
FABP1 21.460.1 214.99 210.060.6 248.54 216.660.2
DKK1 26.67 22.560.7 28.70 210.061.0 212.82 29.061.0
KLB 23.04 27.860.07 22.59 28.561.0 211.09 230.063.0
DDIT3 2.43 1.860.2 5.28 2.760.2 7.14 1.760.3
TRIB3 2.86 1.460.04 3.92 1.360.06 15.10 1.460.01
B. Huh7 cells
Gene CLX SOR SOR+CLX
microarray RT-PCR Q-PCR microarray RT-PCR Q-PCR microarray RT-PCR Q-PCR
LARP6 3.71 4.060.5 7.32 10.862.0 10.75 21.463.0
HRK 3.43 16.660.5 12.88 32.062.0
FABP1 22.76 21.660.3 25.43 22.560.2 216.69 23.360.2
DKK1 24.02 217.563.0 219.46 2125.068.0 252.08 252.060.7
FGF19 22.25 212.562.0 23.04 226.560.5
KLB 29.52 214.063.0
FNDC3B 22.260.5 22.79 24.061.0 22.56 22.560.5
CCND1 22.48 26.661.5 23.01 28.861.0
DDIT3 2.41 7.961.0 10.21 40.065.0 12.94 74.567.0
TRIB3 21.460.1 2.38 2.660.2 2.62 2.660.5
MT2A 4.13 2.360.6 10.71 2.660.3 15.02 3.660.1
doi:10.1371/journal.pone.0065569.t003
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especially in Huh7 cells, suggesting that in some HCC cell types
these drugs might also act through inhibition of this important
regulator of cell proliferation.
FNDC3B is an amplified oncogene which is part of a larger
amplicon encompassing several genes, and often the entire
chromosomal arm of 3q. This gene has been shown to be
frequently amplified more than 30% in esophageal, lung, ovarian
and breast cancers [48]. In HCC, the FNDC3B gene was recently
identified upon oncogenomic screening for amplified oncogenes,
together with CCND1 gene [46]. In addition, FNDC3B overex-
pression induced tumorigenicity in nonmalignant murine hepato-
cytes, suggesting its important role in hepatocarcinogenesis [48].
Klotho-beta (KLB) is a 130 kDa trans-membrane protein which
acts as an FGFR4 co-receptor required for FGF19 binding,
intracellular signaling, and downstream modulation of gene
expression [49]. Recently, it was reported that KLB is overex-
pressed in HCC tumors, and that KLB gene silencing in HCC cells
decreases cell proliferation and suppresses FGFR4 downstream
signaling [50]. Therefore, this study suggests that KLB may be a
novel target for therapeutic intervention in HCC. Of note, we
observed that KLB was reduced using SOR and CLX alone, but
also in a synergistic manner upon combination treatment,
especially in HepG2 cells, suggesting that in some HCC subtypes
KLB may be a good therapeutic target.
Conclusion
In conclusion, combined SOR+CLX treatment displayed
strong synergistic cytotoxic effects in both HepG2 and Huh7
cells. Gene expression studies were confirmative for this synergism,
as for each cell line, the combined treatment was associated with
the modulation of distinct sets of genes, quite different from those
displaying altered expression upon individual drug’s treatment.
Moreover, each cell line exhibited rather unique patterns of
differential gene expression following combined SOR+CLX
treatment, which confirms our previous findings for the specific
mode of cytotoxic action of both these drugs in HepG2 and Huh7
cells. These analyses, as well as consecutive validation studies
based on mRNA and protein expression levels, identified several
new gene targets of individual drugs and of the SOR+CLX
combination. Further functional analyses will determine whether
these genes may serve as potential molecular targets for more
effective strategies for the treatment of HCC. Finally, our findings
suggest the possible application of combined SOR+ CLX therapy
in HCC patients.
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